AWAidan P. G. Walsh

Aidan P. G. Walsh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aidan P. G. Walsh has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mapping Hydration and Nanoarchitecture in mRNA‐Loaded Lipid Nanoparticles Through Small‐Angle Neutron Scattering

    by Haikun Liu, Mark Louis P. Vidallon, Sylvain Trépout, Marina Cagnes, Nageshwar Rao Yepuri, Tamim Darwish, Mitchell J. Moon, Pengkai Shi, Aidan P. G. Walsh, Rico F. Tabor, et al.

    MRNA‐loaded lipid nanoparticles (LNPs) offer significant therapeutic potential for various diseases, yet their structural characteristics and component distribution remain incompletely understood. This study utilizes small‐angle neutron scattering (SANS) to explore the internal architecture of KC2 LNPs, employing deuterated lipid substitutions in contrast‐varied media. Our analyses reveal that KC2 LNPs have diameters of 50–60 nm, consistent with cryogenic transmission electron microscopy (cryoTEM) and dynamic light scattering. Core–shell modeling indicates a core radius of 16–17 nm and a shell thickness of 6–8 nm, details often overlooked by cryogenic electron microscopy. Interestingly, results demonstrated that LNPs contain 48%–55% water (total particle volume), which is highly exchangeable with the dispersing medium. This water exchange is crucial during structural monitoring under conditions simulating endosomal environments, as acidification leads to an internal structural reorganization, involving solvent influx into the LNPs and potentially reorganization of components within and across the core and shell phases. Invariant analysis further confirms the high water content of LNPs, validating the model fitting results, affirming KC2 LNPs’ compositional complexity, which are pivotal for understanding LNP stability and responsiveness. These insights can guide the future design of mRNA nanotherapeutics, enhancing their therapeutic efficacy.


  • Open Access

    Endothelial-targeted CD39 prevents Toxin-induced Pulmonary Hypertension Mice

    by Abbey Willcox, Ioanna Savvidou, Natasha Ting Lee, Carly Selan, Ilaria Calvello, Simon C. Robson, Viktoria Bongcaron, Aidan Walsh, Yuyang Song, Xiaowei Wang, et al.

    Disruption of the pulmonary endothelium by drugs, toxins, viruses (e.g., COVID-19), or bacterial sepsis can cause acute pulmonary vasculopathy leading to pulmonary hypertension and consequential heart failure. CD39 is a membrane-anchored ecto-enzyme expressed on endothelial cells (EC), integral in maintaining the antithrombotic profile of the endothelium. This ecto-enzyme works in concert with CD73 to hydrolyze both eATP (pro-inflammatory) and ADP (pro-thrombotic) ultimately to adenosine, which is anti-inflammatory, vasodilatory, and antithrombotic. CD39 activity and adenosine signalling are disrupted in idiopathic pulmonary arterial hypertension (PAH). In this work, we explored the efficacy of endothelial cell-targeted delivery of CD39 to prevent the development of acute toxin-induced PAH in a mouse model. We generated a novel therapeutic anti-VCAM-CD39 containing an scFv recognising VCAM-1 (a receptor expressed on activated EC) fused to the soluble form of extracellular human CD39. In a mouse model of endothelial cell-toxin-induced PAH, we show that a single administration of anti-VCAM-CD39 (0.4 mg/kg IV) prevented the development of PAH— as reflected in the preservation of right ventricular systolic pressures and the absence of right ventricular hypertrophy at day 10 when compared with controls. This protection is conferred by multiple mechanisms: IL-10-driven potentiation of heme oxygenase (HO)-1, a known inhibitor of smooth muscle proliferation; VCAM-1 blockade reduces leukocyte adhesion to the endothelium; and cytoprotective effects through adenosine signalling. Thus, anti-VCAM-CD39 is a novel bifunctional therapeutic strategy for PAH.

  • Activated Coagulation FXII: A Unique Target for In Vivo Molecular Imaging

    by Aidan P.G. Walsh, Eefang Yu, James D. McFadyen, Viktoria Bongcaron, Mitchell J. Moon, Angela Huang, Jane F. Arthur, Ineke L. Muir, Veronika Rayzman, Con Panousis, et al.

    Background: Current clinical imaging of thromboembolic diseases often relies on indirect detection of thrombi, which may delay diagnosis and ultimately the institution of beneficial, potentially lifesaving treatment. Therefore, the development of targeting tools that facilitate the rapid, specific, and direct imaging of thrombi using molecular imaging is highly sought after. One potential molecular target is FXIIa (factor XIIa), which initiates the intrinsic coagulation pathway but also activates the kallikrein-kinin system, thereby initiating coagulation and inflammatory/immune responses. As FXII (factor XII) is dispensable for normal hemostasis, its activated form (FXIIa) represents an ideal molecular target for diagnostic and therapeutic approaches, the latter combining diagnosis/identification of thrombi and effective antithrombotic therapy. Methods: We conjugated an FXIIa-specific antibody, 3F7, to a near-infrared (NIR) fluorophore and demonstrated binding to FeCl 3 -induced carotid thrombosis with 3-dimensional fluorescence emission computed tomography/computed tomography and 2-dimensional fluorescence imaging. We further demonstrated ex vivo imaging of thromboplastin-induced pulmonary embolism and detection of FXIIa in human thrombi produced in vitro. Results: We demonstrated imaging of carotid thrombosis by fluorescence emission computed tomography/computed tomography and measured a significant fold increase in signal between healthy and control vessels from mice injected with 3F7-NIR compared with mice injected with nontargeted probe ( P =0.002) ex vivo. In a model of pulmonary embolism, we measured increased NIR signal in lungs from mice injected with 3F7-NIR compared with mice injected with nontargeted probe ( P =0.0008) and healthy lungs from mice injected with 3F7-NIR ( P =0.021). Conclusions: Overall, we demonstrate that FXIIa targeting is highly suitable for the specific detection of venous and arterial thrombi. This approach will allow direct, specific, and early imaging of thrombosis in preclinical imaging modalities and may facilitate monitoring of antithrombotic treatment in vivo.